Online inquiry

IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1624MR)

This product GTTS-WQ1624MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets F10&F9 gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000504.4; NM_000133.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2159; 2158
UniProt ID P00742; P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1624MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12776MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ1353MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ14101MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aNGF75
GTTS-WQ6168MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ5419MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ5307MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ8159MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ15906MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA XOMA 052
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW